Rezultati - Jesper Stentoft

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

    Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML od Rebecca Warfvinge, Linda Geironson, Mikael N.E. Sommarin, Stefan Lang, Christine Karlsson, Teona Roschupkina, Leif Stenke, Jesper Stentoft, Ulla Olsson‐Strömberg, Henrik Hjorth‐Hansen, Satu Mustjoki, Shamit Soneji, Johan Richter, Göran Karlsson

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

    Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial od Jerald P. Radich, Andreas Hochhaus, Tamás Masszi, Andrzej Hellmann, Jesper Stentoft, María Teresa Gómez‐Casares, Valentín García‐Gutiérrez, Eibhlin Conneally, Philipp D. le Coutre, Norbert Gattermann, Bruno Martino, Susanne Saußele, Francis J. Giles, David M. Ross, Paola Aimone, Sai Li, Ksenia Titorenko, Giuseppe Saglio

    Izdano 2021
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

    Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients od Henrik Hjorth‐Hansen, Jesper Stentoft, Johan Richter, Perttu Koskenvesa, Martin Höglund, Arta Dreimane, Kimmo Porkka, Tobias Gedde‐Dahl, Bjørn Tore Gjertsen, Franz Gruber, Leif Stenke, Kristina Myhr Eriksson, Berit Markevärn, Anna Lübking, Hanne Vestergaard, Lene Udby, Ole Weis Bjerrum, Inger Persson, Satu Mustjoki, Ulla Olsson‐Strömberg

    Izdano 2016
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

    Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study od David M. Ross, Tamás Masszi, María Teresa Gómez‐Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentín García‐Gutiérrez, Norbert Gattermann, Philipp D. le Coutre, Bruno Martino, Susanne Saußele, Francis J. Giles, Jerald P. Radich, Giuseppe Saglio, Weiping Deng, Nancy Krunic, Véronique Bédoucha, Prashanth Gopalakrishna, Andreas Hochhaus

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

    Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial od Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saußele, Perttu Koskenvesa, Leif Stenke, Satu Mustjoki, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf‎, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde‐Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth‐Hansen, Jeroen J.W.M. Janssen, Ulla Olsson‐Strömberg

    Izdano 2024
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

    Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study od Andreas Hochhaus, Tamás Masszi, Francis J. Giles, Jerald P. Radich, David M. Ross, María Teresa Gómez‐Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentín García‐Gutiérrez, Norbert Gattermann, W Wiktor-Jędrzejczak, Philipp D. le Coutre, B. Martino, Susanne Saußele, Hans D. Menssen, Weiping Deng, Nancy Krunic, Véronique Bédoucha, Giuseppe Saglio

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

    Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia od Bengt Simonsson, Tobias Gedde‐Dahl, Berit Markevärn, Kari Remes, Jesper Stentoft, A. Almqvist, Mats Björeman, Max Flogegård, Perttu Koskenvesa, Anders Lindblom, Claes Malm, Satu Mustjoki, Kristina Myhr‐Eriksson, Lotta Ohm, Anu Räsänen, Marjatta Sinisalo, Anders Själander, Ulla Strömberg, Ole Weiss Bjerrum, Hans Ehrencrona, Franz Gruber, Veli Kairisto, Karin Olsson, Fredrik Sandin, Arnon Nagler, Johan Lanng Nielsen, Henrik Hjorth‐Hansen, Kimmo Porkka

    Izdano 2011
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

    Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses od Trine Alma Knudsen, Vibe Skov, Kristen E. Stevenson, Lillian Werner, William S. Duke, Charles Laurore, Christopher J. Gibson, Anwesha Nag, Aaron R. Thorner, Bruce M. Wollison, Dennis Lund Hansen, Christina Ellervik, Daniel El Fassi, Karin de Stricker, Lukas Frans Ocias, Mette Brabrand, Ole Weis Bjerrum, Ulrik Malthe Overgaard, Mikael Frederiksen, Thomas Kielsgaard Kristensen, Torben A. Kruse, Mads Thomassen, Torben Mourits‐Andersen, Marianne Tang Severinsen, Jesper Stentoft, Joern Starklint, Donna Neuberg, Lasse Kjær, Thomas Stauffer Larsen, Hans Carl Hasselbalch, R. Coleman Lindsley, Ann Mullally

    Izdano 2021
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: